Dementia-related psychosis data could make Acadia’s pimavanserin a blockbuster

Pivotal data reported late Wednesday support Acadia’s bid for a label expansion that would bring pimavanserin to the broader population of dementia-related psychosis and help allay safety concerns associated with a black box on the drug’s label.

Shares of Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) gained $6.20 (14%) to $50.48 Thursday,

Read the full 498 word article

User Sign In